GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » EV-to-EBITDA

Aequus Pharmaceuticals (Aequus Pharmaceuticals) EV-to-EBITDA : -3.48 (As of May. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aequus Pharmaceuticals's enterprise value is $4.33 Mil. Aequus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.24 Mil. Therefore, Aequus Pharmaceuticals's EV-to-EBITDA for today is -3.48.

The historical rank and industry rank for Aequus Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

AQSZF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -87.39   Med: -4.78   Max: -1.77
Current: -3.48

During the past 10 years, the highest EV-to-EBITDA of Aequus Pharmaceuticals was -1.77. The lowest was -87.39. And the median was -4.78.

AQSZF's EV-to-EBITDA is ranked worse than
100% of 704 companies
in the Drug Manufacturers industry
Industry Median: 14.56 vs AQSZF: -3.48

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Aequus Pharmaceuticals's stock price is $0.00895. Aequus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.007. Therefore, Aequus Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Aequus Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Aequus Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals EV-to-EBITDA Chart

Aequus Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.77 -5.13 -44.55 -12.22 -2.49

Aequus Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.89 -5.37 -3.82 -2.49 -5.08

Competitive Comparison of Aequus Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aequus Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's EV-to-EBITDA falls into.



Aequus Pharmaceuticals EV-to-EBITDA Calculation

Aequus Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4.332/-1.244
=-3.48

Aequus Pharmaceuticals's current Enterprise Value is $4.33 Mil.
Aequus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals  (OTCPK:AQSZF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Aequus Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00895/-0.007
=At Loss

Aequus Pharmaceuticals's share price for today is $0.00895.
Aequus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.007.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Aequus Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.